Erbitux Sales Data
Last updated: February 2014 (updated quarterly).
The following data shows Erbitux U.S. retail sales in Q4 2013 compared to previous quarters.
|Date Range||Sales Rank||Sales ($000)||Units (000)|
|Q2 2012||95 (4)||$167,914||-2.10%||262||-1.50%|
|Q1 2012||99 (2)||$171,513||2.30%||266||3.91%|
|Q4 2011||97 (7)||$167,657||-0.15%||256||0.79%|
|Q3 2011||90 (3)||$167,909||-2.48%||254||-1.93%|
|Q2 2011||93 (2)||$172,185||-0.89%||259||-0.38%|
* Units refer to the number of packages sold.
|December 23, 2013||EU OKs Erbitix Labeling|
|July 9, 2012||FDA Oks Screening Test for Colon Cancer Drug|
|November 7, 2011||Erbitux Approval Expanded to Include Head and Neck Cancer|
|June 9, 2011||Chemo for Late-Stage Cancer Patients May Be Unjustified|
|December 20, 2010||Rash Due to Lung Cancer Drug May Be Linked to Better Survival|
|October 26, 2010||New Insights on Who Should Take Erbitux for Colon Cancer|
|October 11, 2010||Erbitux Drug Fails In Colon Cancer Study That May Limit Its Use|
|April 1, 2009||Erbitux May Help Some With Colorectal Cancer|
|October 22, 2008||Colon Cancer Drug Won't Help Those With Certain Gene Mutation|